Several small-cap biotech and healthcare stocks posted notable gains in after-hours trading on Friday, November 28, 2025, despite limited fresh news flow. Below is a roundup of the key movers.BioAtla Inc. (BCAB) shares surged in after-hours trading, climbing 13.94% to $1.03, after closing the regular session at $0.9040, up 6.27%. While there was no company-specific news on Friday, investors may still be reacting to BioAtla's November 21 announcement of financing agreements. The company entered into Pre-pai ...

Exhibit 99.1 Financial Results for September 30, 2025 Reviva Reports Third Quarter 2025 Financial Results and Recent Business Highlights – Pre-NDA meeting with FDA to discuss brilaroxazine's path to approval for schizophrenia planned in Q4 2025 – – Potential NDA submission for schizophrenia indication targeted for Q2 2026 – – European patent granted covering use of brilaroxazine for the treatment of pulmonary fibrosis adds to existing patent protection in key global markets – Cupertino, Calif., November 13, ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____ to ____ Commission file number: 001-38634 Reviva Pharmaceuticals Holdings, Inc. (Exact name of registrant as specified in its charter) incorporation ...

– Pre-NDA meeting with FDA to discuss brilaroxazine’s path to approval for schizophrenia planned in Q4 2025 – – Potential NDA submission for schizophrenia indication targeted for Q2 2026 – – European patent granted covering use of brilaroxazine for the treatment of pulmonary fibrosis adds to existing patent protection in key global markets – CUPERTINO, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical comp ...

Core Insights - Reviva Pharmaceuticals Holdings, Inc. is a late-stage pharmaceutical company focused on developing therapies for unmet medical needs in CNS, inflammatory, and cardiometabolic diseases [1][3] - The company will present findings on the anti-inflammatory effects of brilaroxazine from the Phase 3 RECOVER trial at the 2025 Neuroscience meeting [1][2] Company Overview - Reviva's pipeline includes two drug candidates: brilaroxazine (RP5063) and RP1208, both of which are new chemical entities discovered in-house [3] - The company has secured composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries [3]

- Patent covers brilaroxazine use for treating Pulmonary Fibrosis -Similar patents have also been granted in key markets around the world including the United States, China, and Japan -Brilaroxazine has a novel mechanism of action for treating the underlying disruption in serotonin signaling implicated in the pathogenesis of Pulmonary Fibrosis CUPERTINO, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical com ...

Core Insights - Reviva Pharmaceuticals Holdings, Inc. is a late-stage pharmaceutical company focused on developing therapies for unmet medical needs in central nervous system (CNS), inflammatory, and cardiometabolic diseases [1][4] - The company will be represented by its Founder, President, and CEO, Laxminarayan Bhat, at the Spartan Capital Securities Second Annual Investor Conference on November 3, 2025, in New York City [1] Company Overview - Reviva's current pipeline includes two drug candidates: brilaroxazine (RP5063) and RP1208, both of which are new chemical entities discovered in-house [4] - The company has been granted composition of matter patents for both drug candidates in the United States, Europe, and several other countries [4] Conference Details - The Spartan Capital Securities conference will feature over 60 selected companies across various sectors, including technology, healthcare, and consumer [2] - More than 500 institutional and high-net-worth investors are expected to attend, providing opportunities for dialogue between growth companies and the investment community [2]

Core Insights - Reviva Pharmaceuticals Holdings, Inc. is a late-stage pharmaceutical company focused on developing therapies for unmet medical needs in CNS, inflammatory, and cardiometabolic diseases [1][3] - The company will present negative symptom data for brilaroxazine from the Phase 3 RECOVER trial at the CNS Summit 2025 [1][2] Company Overview - Reviva's pipeline includes two drug candidates: brilaroxazine (RP5063) and RP1208, both of which are new chemical entities discovered in-house [3] - The company has secured composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries [3]

Group 1: Reviva Pharmaceuticals Holdings, Inc. (RVPH) - RVPH is a clinical-stage biopharmaceutical company focused on therapies for central nervous system, respiratory, and metabolic diseases [1] - The current trading price is $0.44, with a target price of $0.39, indicating a potential downside of approximately -11.09% [1] - The significant gap between the current and target price suggests a pessimistic outlook from investment analysts, leading to its exclusion from coverage [1] Group 2: PDS Biotechnology Corporation (PDSB) - PDSB is trading at $0.93, with a discounted cash flow (DCF) valuation of $0.54, resulting in a price percentage difference of -41.72% [2] - The market cap of PDSB is $43.63 million, and it has an earnings per share (EPS) of -0.91, with a negative price-to-earnings (P/E) ratio of -1.58 [2] - This reflects the company's current unprofitability [2] Group 3: IO Biotech, Inc. (IOBT) - IOBT has a current stock price of $1.17 and a DCF valuation of $0.88, leading to a price percentage difference of -24.60% [3] - The market cap of IOBT is $77.08 million, with an EPS of -1.58 and a P/E ratio of -0.63 [3] - This indicates that IOBT is also trading above its intrinsic value, similar to PDSB, but with a slightly better valuation [3] Group 4: Skye Bioscience, Inc. (SKYE) - SKYE has a current stock price of $1.47 and a DCF valuation of $1.86, resulting in a positive price percentage difference of 26.28% [4] - The market cap of SKYE is $45.71 million, with an EPS of -1.06 and a P/E ratio of -3.89 [4] - This suggests that SKYE is undervalued compared to its intrinsic value, indicating potential growth despite current losses [4]

Core Insights - Reviva Pharmaceuticals Holdings, Inc. is a late-stage pharmaceutical company focused on developing therapies for unmet medical needs in CNS, inflammatory, and cardiometabolic diseases [1][4] - The company will participate in a fireside chat and KOL webinar on October 10, 2025, featuring discussions on schizophrenia treatment and clinical data for its lead drug candidate, brilaroxazine [1][2] Company Overview - Reviva's pipeline includes two drug candidates: brilaroxazine (RP5063) and RP1208, both of which are new chemical entities discovered in-house [4] - The company has secured composition of matter patents for both drug candidates in the United States, Europe, and several other countries [4]